Stage III Gastric Cancer Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Stage III Gastric Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled369 locationsNCT06203600
Recruiting
Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 3

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology382 enrolled786 locationsNCT05677490
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled740 locationsNCT05334069
Recruiting
Early Phase 1

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+30 more
M.D. Anderson Cancer Center15 enrolled1 locationNCT05041153
Recruiting
Not Applicable

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8+9 more
University of Washington66 enrolled1 locationNCT05911243
Recruiting
Phase 2

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+28 more
Academic and Community Cancer Research United116 enrolled15 locationsNCT04660760
Recruiting
Not Applicable

Immunonutritional Supplement After Total Gastrectomy in Patients With Stage III Gastric Cancer

Stage III Gastric Cancer
Jinling Hospital, China696 enrolled1 locationNCT05253716